Summit Therapeutics Inc.

Summit Therapeutics Inc.'s Audit Committee and all independent directors have approved company affiliates to purchase shares of common stock under its existing at-the-market (ATM) offering. Separately, Co-Chief Executive Officers Robert Duggan and Mahkam Zanganeh, along with Chief Operating Officer and Chief Financial Officer Manmeet Soni, have indicated their likely intent to purchase shares under the ATM in the near term, though no specific number of shares or binding commitments have been made.

Summit Therapeutics announced positive overall survival (OS) results from the Phase III HARMONi-6 trial for ivonescimab in first-line squamous non-small cell lung cancer (NSCLC), conducted by its partner Akeso in China. Ivonescimab plus chemotherapy reduced the risk of death by 34% (HR 0.66) compared to tislelizumab plus chemotherapy, with 24-month OS rates of 64.7% vs. 48.6%. Additionally, encouraging global Phase II data for ivonescimab in first-line metastatic colorectal cancer (mCRC) from the AK112-206 trial showed an objective response rate (ORR) of 70.8% and a manageable safety profile. The company will discuss these results in a conference call.

Summit Therapeutics Inc. reported a significant net loss of $189.4 million for the first quarter of 2026, a substantial increase from the prior year, driven by higher research and development and general and administrative expenses. The company's cash and cash equivalents declined significantly, leading management to express substantial doubt about its ability to continue as a going concern. Summit is focused on the development of its lead candidate, ivonescimab, and is evaluating options to raise additional capital.

Summit Therapeutics Inc. reported its Q1 2026 financial results and provided significant clinical updates for ivonescimab. Key highlights include the upcoming presentation of HARMONi-6 overall survival data at the ASCO 2026 Plenary Session and the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab with a PDUFA date of November 14, 2026. The company also updated on HARMONi-3 trial progress, expecting final PFS data for the squamous cohort in H2 2026 and for the non-squamous cohort in H1 2027. Financially, Summit reported a GAAP net loss of $(189.4) million and a non-GAAP net loss of $(116.6) million for the quarter, with cash and short-term investments totaling $598.7 million.